



M U N I
M E D

ANTIMYCOTICS


Bacterium



Fungus



Human



M U N I

M E D [↑] Incidence:

MYCOSES

immunodeficiency, HIV, ...
DM

radiotherapy, chemotherapy, neutropaenic patients

Classification:

pathogen: candidosis
aspergillosis
cryptococcosis
zygomycosis


localization: systemic
organ
mucosal
skin

Monitoring of disease progression - determination of serum

- Panfungal (1 → 3) - β -D-Glucan
- Galactomannan (aspergillus inf.)

ANTIMYCOTICS

Specific



Systemic

+

Topical

- polyenes

- azoles


- allylamines


- antimetabolites

- others

M U N I
M E D


ANTIMYCOTICS





Overview of antimycotics

Polyenes	systemic	<i>amphotericin B</i>
	topical	<i>nystatin</i> <i>natamycin</i>
Antimetabolites		<i>flucytosin</i>
Azoles	systemic	<i>ketoconazole, miconazole,</i> <i>fluconazole, itraconazole</i>
	topical	<i>econazole, clotrimazole, terconazole</i>
Allylamines	systemic	<i>terbinafin, naftifin</i>
others	systemic	<i>griseofulvin, caspofungin</i>
	topical	<i>ciclopiroxolamin, tolnaftate</i>



POLYENE ANTIMICOTICS

Amphotericin B

- Broadest spectrum, lowest resistance
- Quite highly toxic, most of patients perceive some grade of toxicity/AE
- Drug of choice in aspergiloses

MA: binding to ergosterol in cell wall

Pharmacokinetics: poor GIT bioavailability, administered i.v.- lipidic complex (ABLC)

Toxicity

Acute manifestations: fever, chills, rigor, nausea, vomiting, headache, muscle pain, joint pain, allergies, thrombophlebitis

Chronic manifestations: nephrotoxicity (total dose reversibility) followed by electrolyte imbalance, normocytic normochromic anemia (therapy: erythropoietin)

Nystatin (*Streptomyces noursei*)

- again yeasts
- p.o. candidosis in GIT

Natamycine (*Streptomyces natalensis*)

- against candidoses and *Trichomonas* infections

Flucytosine (5-fluorocytosine)

MA: inhibition of nucleic acid synthesis

- narrow spectrum – candida, cryptococcus
- amphotericine combined treatment = spectrum widening

AE: granulocytopenia, GIT intolerance

MA: inhibition of C-14- α -demethylase (CYP450)

IT: CYP and Pgp inhibition !!!

Classification:

topical / systemic

imidazoles / triazoles

Systemic

Imidazoles:

Miconazole - block of tromboxansynthetase

Ketoconazole - steroidogenesis inhibition

Triazols:

Itraconazole – imunomodulative

Fluconazole

Voriconazole

M U N I M E D

AZOLES

topical

Econazol

- also efficient against some bacterias

Clotrimazol

- depo in *stratum corneum*
- hepatic metabolism after absorption

Fenticonazol

Tioconazol

	CYP1A2	CYP2C9	CYP2C8	CYP2C19	CYP2D6	CYP3A4	PgP
Fluconazole	0/?	↓	0/?	↓	0/?	S/↓	0
Itraconazole	0/↑CYP1A1	↓	0	0	0	S/↓	↓
Voriconazole	0	S/↓	0	S/↓	0	S/↓	?
Posaconazole	0	0	0	0	0	↓	S
Ketoconazole	0/?	↓	0/?	↓	0/?	S/↓	S/↓

ECHINOCANDINS

= lipopeptides

Caspofungin

MA: inhibition of β -1,3-D-glucan synthesis
(cell wall component of many fungi and yeasts)

- parenteral administration
- synergism when combined with azoles or polyenes
- not metabolized via CYP

I: alternative therapies for severe mycoses (aspergillosis)

Systemic – **Terbinafine**

MofA: block of squalenepoxidase

- administered orally
- cummulation in the adipose tissue and skin
- synergistic effect with ketoconazole

AE: dyspepsia, loss of apetite

Griseofulvin

Narrow spectrum, fungistatic

MA: interaction with microtubules – mitotic poison

- administered orally
- cummulation in stratum corneum, hair, nails
- local effect on skin
- I: dermatomycoses

AE: GIT irritation, alergy, leucopenia, hepatotoxicity, nerologic disorders

Ciclopirox-olamine

topical fungicidal antimycotic agent

+ G+/G- bacteria, mycoplasmas, trichomonades

MA: chelates Fe³⁺ (⇒ metalloproteins function abruption)

⇒ cytochrom – blocks energy metabolism of the mycotic cell

⇒ catalase, peroxidase – block antioxidative protection

Cytoplasmatic membrane – block of transporters

- deplete essent. AA (Leu), nukleotides, ..

antioxidant - scavenger ROS (OH•)

inhibitor AA ⇒ inh. Synthesis a LT in human PMN cells

antiinflammatory aktivty in vivo - 2,5 % hydrokortison